The global Postpartum Hemorrhage Devices Market valued at USD 840 Mn by 2021 expected to reach USD 1166 Mn by 2028 growing at a CAGR of 4.8% during the forecast period 2022 to 2028. Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Rising pregnancy difficulties such as multiple pregnancies, tilted uterus, and large baby size are significant factors for the Postpartum Hemorrhage Devices Market expansion. Furthermore, rising postpartum haemorrhage risk factors such as uterine atony, trauma, and anaemia cases in pregnant women, as well as technological advancements such as the devices’ ability to stabilise the patient’s condition until permanent treatment is provided, are propelling the PPH devices market forward. The lack of healthcare resources in poor nations, as well as the expensive cost of equipment, are projected to stifle the market for postpartum haemorrhage (PPH) devices. One of the causes of postpartum haemorrhage in pregnant women is anaemia, a major nutritional condition. According to research published by the National Center for Biotechnology Information in 2008, severe anaemia can damage the immune system, contributing to postpartum haemorrhage. PPH can be treated with first-line (non-surgical) techniques such as the use of uterotonic medicines like oxytocin and misoprostol. Second-line intervention devices, such as non-pneumatic anti-shock garments, uterine balloon tamponade, and Uniject prefilled injectable systems, are used when medications are not available. Because these devices are successful in stopping blood flow and stabilising the patient’s condition until more comprehensive care is delivered.